Montefiore Medical Center, Bronx, NY
So Yeon Kim , Stephen Bohlman , Jun Yin , Haiying Cheng , Phillip Walker , Sanja Dacic , Chul Kim , Hina Khan , Stephen V. Liu , Patrick C. Ma , Misako Nagasaka , Karen L. Reckamp , Jim Abraham , Dipesh Uprety , Balazs Halmos
Background: Multiple DNA alterations in exon 14 splice sites have been identified in NSCLC and result in skipping of the juxtamembrane domain Cbl-E3 ubiquitin ligase binding region, leading to increased MET stability and oncogenesis. The effects of these alterations on transcriptome-level have not been fully characterized. We present the largest cohort study of METex14 using WTS and identify key cellular pathways associated with invasion and metastases in METex14. Methods: 17,666 NSCLC tumor samples underwent genomic profiling at Caris Life Sciences. Analyses included next generation sequencing of DNA (592 Gene Panel, NextSeq, whole exome sequencing, NovaSeq) and RNA (NovaSeq, WTS). METex14 was captured via WTS. ssGSEA analysis was used to evaluate pathway enrichment. Wilcoxon, Fisher’s exact were used for statistical significance (p without and q values with multiple comparison correction). Results: 440 patients (2.5%) with METex14 were identified. METex14 patients were of older age, female gender, and enriched in sarcomatoid histology (Table 1). The most common alterations were point mutations (51.5%) and deletions (17.3%) at donor splice sites. Splice site alterations except point mutations at splice acceptor site translated to increased mRNA expression compared to wild-type MET (WT). MET amplification translated to higher mRNA expression compared to METex14 and WT with synergistic expression when co-altered with METex14 (q<0.05). The most common co-alterations were amplifications of MDM2 (18.5% vs. 1.8% WT), HMGA2 (13.7% vs 0.9% WT), and CDK4 (10.4% vs 1.4% WT) (q < 0.05). METex14 were mutually exclusive to mutations in KRAS and EGFR. High PD-L1 (22c3) > 50% (53% vs. 27.6% WT, q<0.001) and lower TMB (4 mut/Mb vs. 7 mut/Mb WT, p<0.001) were observed with METex14 and pathways associated with skipping variants included IFNγ signaling, angiogenesis, and apical junction pathways on univariate analysis (q<0.05). Conclusions: We present the largest WTS analysis of METex14. Splicing alterations and MET co-amplification translated to higher and synergistic MET expression at transcriptome level, respectively. Association with upregulated angiogenic and apical junction pathways support preclinical observation of vascular and cytoskeletal remodeling as potential mechanisms of invasion and metastases in MET ex14 NSCLC.
METex14 (N) | WT (N) | q-value | Alteration | % | mRNA expression relative to WT | |
---|---|---|---|---|---|---|
Male | 192 | 8673 | <0.05 | |||
Female | 248 | 8553 | Donor splice site point mutation | 51.5 | 3.5 | |
Age, median | 77 | 69 | <0.0001 | Donor splice site deletion | 17.3 | 4 |
Adenocarcinoma | 273 | 10203 | <0.001 | Polypyrimidine site deletion | 16.5 | 4 |
Squamous | 49 | 3878 | Acceptor splice site deletion | 7.5 | 4 | |
Adenosquamous | 10 | 147 | Acceptor splice site point mutation | 2.1 | 1 | |
Sarcomatoid | 11 | 104 | METex14 + MET Amp | 0.07 | 24.4 | |
Large cell | 1 | 45 | MET Amp | 0.89 | 14.1 | |
others | 96 | 2831 | METex14 | 2.45 | 3.3 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Annual Meeting
First Author: Mariana da Rocha Almeida Brandao
2022 ASCO Annual Meeting
First Author: Jennifer Aline Marks
2023 ASCO Annual Meeting
First Author: Jennifer Aline Marks
2024 ASCO Annual Meeting
First Author: Yang Song